相似文献
1
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer.
Geburtshilfe Frauenheilkd. 2016 Feb;76(2):147-149. doi: 10.1055/s-0035-1568169.
2
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer.
Bull Cancer. 2024 Mar;111(3):277-284. doi: 10.1016/j.bulcan.2023.02.011. Epub 2023 Mar 24.
3
Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer.
Geburtshilfe Frauenheilkd. 2013 Mar;73(3):221-223. doi: 10.1055/s-0032-1328320.
4
Correction to: The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Kommission Ovar, AGO Study Group, North-Eastern German Society of Gynaecologic Oncology (NOGGO), AGO Austria and AGO Switzerland.
Arch Gynecol Obstet. 2018 Apr;297(4):847. doi: 10.1007/s00404-018-4715-7.
5
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO.
Int J Gynecol Cancer. 2011 Feb;21(2):289-95. doi: 10.1097/IGC.0b013e31820aaafd.
6
Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
J Visc Surg. 2014 Oct;151(5):347-53. doi: 10.1016/j.jviscsurg.2014.07.005. Epub 2014 Aug 29.
7
[Ovarian cancer -- can peritoneal therapy be regarded as new standard?].
Zentralbl Gynakol. 2006 Aug;128(4):202-6. doi: 10.1055/s-2006-933460.
8
Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Minerva Chir. 2014 Feb;69(1):27-35.
9
Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data.
Expert Rev Anticancer Ther. 2012 Jul;12(7):895-911. doi: 10.1586/era.12.72.
10
Both heat and new chemotherapeutic drug dioxadet in hyperthermic intraperitoneal chemoperfusion improved survival in rat ovarian cancer model.
J Surg Oncol. 2016 Mar;113(4):438-42. doi: 10.1002/jso.24140. Epub 2015 Dec 29.
引用本文的文献
1
Hyperthermic Intraperitoneal Chemotherapy and Cytoreductive Surgery in Ovarian Cancer: An Umbrella Review of Meta-Analyses.
Front Oncol. 2022 May 9;12:809773. doi: 10.3389/fonc.2022.809773. eCollection 2022.
2
Narrative review of cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases in ovarian cancer.
J Gastrointest Oncol. 2021 Apr;12(Suppl 1):S137-S143. doi: 10.21037/jgo-20-274.
3
Hyperthermic intraperitoneal chemotherapy in ovarian cancer: Qui Bono?
Ann Transl Med. 2020 Dec;8(24):1708. doi: 10.21037/atm-20-1486.
4
Development of new medical treatment for epithelial ovarian cancer recurrence.
Gland Surg. 2020 Aug;9(4):1149-1163. doi: 10.21037/gs-20-413.
5
It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer.
Gynecol Oncol. 2018 Dec;151(3):555-561. doi: 10.1016/j.ygyno.2018.09.007. Epub 2018 Sep 22.
6
Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study.
J Gynecol Oncol. 2018 Jul;29(4):e47. doi: 10.3802/jgo.2018.29.e47. Epub 2018 Mar 8.
本文引用的文献
1
A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer.
Gynecol Oncol. 2015 Jan;136(1):130-5. doi: 10.1016/j.ygyno.2014.11.072. Epub 2014 Nov 28.
2
Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.
Gynecol Oncol. 2015 Jan;136(1):18-24. doi: 10.1016/j.ygyno.2014.09.017. Epub 2014 Oct 2.
3
HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Int J Cancer. 2015 Feb 1;136(3):699-708. doi: 10.1002/ijc.29011. Epub 2014 Jun 17.
4
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience.
Langenbecks Arch Surg. 2014 Jun;399(5):589-94. doi: 10.1007/s00423-014-1207-5. Epub 2014 May 11.
5
S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.
Geburtshilfe Frauenheilkd. 2013 Sep;73(9):874-889. doi: 10.1055/s-0033-1350713.
6
Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer.
Geburtshilfe Frauenheilkd. 2013 Mar;73(3):221-223. doi: 10.1055/s-0032-1328320.
7
Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer.
Gynecol Oncol. 2014 Mar;132(3):537-41. doi: 10.1016/j.ygyno.2014.01.027. Epub 2014 Jan 23.
8
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
J Clin Oncol. 2012 Jun 10;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. Epub 2012 Apr 23.
9
Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients.
J Surg Oncol. 2010 Nov 1;102(6):656-62. doi: 10.1002/jso.21652.
10
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
J Clin Oncol. 2010 Jul 10;28(20):3323-9. doi: 10.1200/JCO.2009.25.7519. Epub 2010 May 24.
Zotero 插件